表浅性膀胱癌灌注化疗的个体化研究  

Clinical research on chemotherapy of transitional cell carcinoma of the bladder

作　　者：张金平[1] 刘会玲[1] 孙颖浩[2] 王林辉[2] 杨庆[2] 杨波[2] 刘毅[1] 

机构地区：[1]解放军第401医院泌尿外科,山东青岛266071 [2]第二军医大学长海医院泌尿外科

出　　处：《临床泌尿外科杂志》2003年第3期148-150,共3页Journal of Clinical Urology

摘　　要：目的 :探讨对表浅性膀胱癌制定个体化膀胱灌注化疗方案的临床意义。方法 :对 48例表浅性膀胱癌标本行原代细胞培养及药物敏感试验 (药敏 ) ,患者随机分为两组 ,一组用丝裂霉素C(MMC)灌注 ,另一组根据药敏结果 ,选择敏感的化疗药物 ,平均随访时间 1 2个月。结果 :各化疗药物的平均抑瘤率 ,原发组分别为吡柔比星 (THP) 50 .0 %、阿霉素 (ADM ) 53 .1 % ,MMC 56 .2 %、米托蒽醌 (MH) 4 7.0 % ,复发组为THP 38.0 %、ADM43 .8% ,MMC 43 .8%、MH 31 .0 % ,组内各化疗药物抑瘤率差异无显著性意义 ,而原发组抑瘤率显著高于复发组 (P <0 .0 5) ;MMC灌注组无瘤率为 58.3 % ,药敏组无瘤率为 79.1 % ,差异有显著性意义 (P <0 .0 5)。结论 :应根据药敏结果 ,选择相对敏感的化疗药物 ,制订个体化膀胱灌注化疗方案 ,以提高疗效 。Purpose:To evaluate the clinical significance of the individual chemotherapy for the treatment of superficial bladder transitional cell cancer.Method:The primary tumor cell culture and the drug sensitive test were done. Forty eight patients were divided into two groups randomly. One group received the chemothcrary treatment with Mitomycin(MMC) and the other with the sensitive drug based on the chemosensitivity assay. The period of follow up was 12 months.Result:The mean tumor inhibiting percent of the routine chemotherapy were 50.0 % for theprubin (THP), 53.1 % for Adriamycin (ADM), 56.2 % for Mitomyan (MMC),and 47.0 % for Mitoxantrone (MH) in the primary group and 38.0 % for THP, 43.8 % for ADM, 43.8 % for MMC, and 31.0 % for MH in the recurrent group.There was no statistical difference among these drugs in respect to the chemotherapy effects. The percent of no tumor recurrence in MMC group was 58.3 % and significantly lower than 79.1 % in MMC sensitive group.Conclusion:The individual chemotherapy and the relative sensitive drugs should be designed and selected so as to decrease the tumor recurrence.

关 键 词：表浅性膀胱癌 灌注化疗 个体化 膀胱内给药 

分 类 号：R737.14[医药卫生—肿瘤]